News

Kineta has been awarded a $6.8m subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant is

Trin Pharma (Trin) has reported that BfArM, the German Regulatory Authority, has approved the start of a Phase I clinical trial of TRIN 2755 in solid tumors. The

Mylan has reported that its privately held Indian subsidiary, Matrix Laboratories, has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Lansoprazole delayed-release

Spectrum Pharmaceuticals (Spectrum) and Nippon Kayaku have entered into an exclusive collaboration for the development and commercialisation of Apaziquone in Asia. Apaziquone is an antineoplastic agent currently being

HealthSport has reported that its strategic manufacturing partner, SMI Manufacturing, has agreed to invest $10m into HealthSport. The investment is expected to accelerate HealthSport’s growth and strengthen its

Bristol-Myers Squibb and Alder Biopharmaceuticals have entered into a global agreement for the development and commercialisation of ALD518. ALD518 is a novel biologic that has completed Phase IIa

The US Department of Veterans Affairs (VA) has awarded a $1.84m grant to Diamyd, a wholly-owned subsidiary of Diamyd Medical, to support the development of Nerve Targeting Drug

Sanofi-aventis and Regeneron Pharmaceuticals (Regeneron) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialise fully-human therapeutic monoclonal antibodies. Both the

Catalyst Pharmaceutical (Catalyst) has reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a